// App-Quantinova.ai

: Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Researchers

Presenter

  • Youn H. Kim

Principal Investigators

  • Sean Whittaker

  • Steven M. Horwitz

  • Madeleine Duvic

  • Oliver Bechter

  • Jose A. Sanches

  • Rudolf Stadler

  • Julia Scarisbrick

  • Pietro Quaglino

  • Pier Luigi Zinzani

  • Pascal Wolter

  • Herbert Eradat

  • Lauren C. Pinter-Brown

  • Pablo L. Ortiz-Romero

  • Oleg E. Akilov

  • Judith Trotman

  • Kerry Taylor

  • Michael Weichenthal

  • Jan Walewski

  • David C. Fisher

  • Marise McNeeley

  • Alejandro A. Gru

  • Yinghui Wang

  • Maria Corinna Palanca-Wessels

  • Julie Lisano

  • Martha Li

  • Hui-Min Lin

  • Meredith Little

  • William L. Trepicchio

  • Reinhard Dummer

Medical Centers

  • Stanford University Cancer Institute, Stanford, CA

  • Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

  • Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil

  • University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany

  • Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham, United Kingdom

  • Dermatologic Clinic, Department of Medical Sciences, Turin University, Turin, Italy

  • Istituto di Ematologia, Bologna, Italy

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • University of California, Irvine, Fullerton, CA

  • Department of Dermatology, University Hospital 12 de Octubre, Madrid, Spain

  • Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA

  • Department of Haematology, Concord Repatriation General Hospital, Sydney, Australia

  • ICON Cancer Care, South Brisbane, Australia

  • Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany

  • Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Quest Diagnostics Nichols Institute, San Juan Capistrano, CA

  • University of Virginia school of medicine, Charlottesville, VA

  • Seattle Genetics, Bothell, WA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Locations

  • United States

  • Australia

  • United Kingdom

  • Belgium

  • Brazil

  • Germany

  • Italy

  • Spain

  • Poland

  • Switzerland

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mycosis fungoides

Biomarkers

  • Cluster of Differentiation 30

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01578499

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved